News & events
Highlights of news and activities at Satya
recent posts
Satya to present preclinical profile of its PARG inhibitors at the 2024 American Association for Cancer Research (AACR) Annual Meeting – April 5-10, San Diego, CA
Abstract title Preclinical profile of novel and potent small molecule inhibitors of PARG Poster number 7112...
Read MoreSatya @ JPM 2024
Satya had meetings with potential partners and collaborators to discuss its portfolio of programs during...
Read MoreSatya to present the preclinical profile of first-in-class RAD51 inhibitors at the Upcoming ESMO Congress – Oct 20-24, Madrid, Spain
Abstract title SAT-122, a potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci...
Read MoreAll posts
Satya to present preclinical profile of its PARG inhibitors at the 2024 American Association for Cancer Research (AACR) Annual Meeting – April 5-10, San Diego, CA
Abstract title Preclinical profile of novel and potent small molecule inhibitors of PARG Poster number 7112...
Read MoreSatya @ JPM 2024
Satya had meetings with potential partners and collaborators to discuss its portfolio of programs during...
Read MoreSatya to present the preclinical profile of first-in-class RAD51 inhibitors at the Upcoming ESMO Congress – Oct 20-24, Madrid, Spain
Abstract title SAT-122, a potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci...
Read MoreSatya to Highlight its SOS1 inhibitors that demonstrate best-in-class single agent activity in preclinical models of KRAS driven tumors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA
Abstract title Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical...
Read MoreSatya to present preclinical profile of its KIF18A inhibitors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA
Abstract title Preclinical profile of novel and potent small molecule inhibitors of KIF18A inhibitors...
Read MoreSatya is at BIO, 2023 – Boston, June 3-6
Satya is attending the BIO at Boston during June 3-6, 2023. Please also visit the...
Read More
Satya chosen as one of the top Promising startups at BIO ASIA 2023
BIO ASIA 2023 held in February 2023 Satya is chosen as one of the most...
Read MoreSatya is at JPM 2023
Please set up a meeting with CSN at murthycsn@satyarx.com
Read MoreSatya is at JPM, 2023
Please set up meetings with CSN at murthcsn@satyarx.com
Read MoreSatya’s MedChem leadership expanded
Navnath Karche, PhD, a Medicinal Chemist with over 18 years of experience across multiple discovery...
Read MoreSatya strengthens Scientific team
Srikant Viswanadha, an accomplished industry leader, has joined Satya as its CSO. Srikant has over...
Read More